<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289431</url>
  </required_header>
  <id_info>
    <org_study_id>685</org_study_id>
    <nct_id>NCT01289431</nct_id>
  </id_info>
  <brief_title>Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis</brief_title>
  <official_title>Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the dose response, and efficacy of Mapracorat
      ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs
      associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>over all study visits post CAC for up to 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival redness</measure>
    <time_frame>over all study visits post CAC for up to 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>at visit 2 (Day 2), post-dose</time_frame>
    <description>Allergy symptoms evaluated by subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>at visit 3, 4, and 5, post-CAC for up to 2 weeks</time_frame>
    <description>Allergy symptoms evaluated by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs</measure>
    <time_frame>at visit 2 (Day 2), post-dose</time_frame>
    <description>Allergy signs evaluated by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs</measure>
    <time_frame>at visit 3, 4, and 5, post-CAC for up to 2 weeks</time_frame>
    <description>Allergy signs evaluated by investigator</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Conjunctivitis, Allergic</condition>
  <arm_group>
    <arm_group_label>Mapracorat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mapracorat Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mapracorat</intervention_name>
    <description>administered daily to each eye for 2 weeks following allergen challenge using a CAC model</description>
    <arm_group_label>Mapracorat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>administered daily to each eye for 2 weeks following allergen challenge using a CAC model</description>
    <arm_group_label>Mapracorat Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  positive history of ocular allergies and a positive skin test reaction

          -  positive bilateral CAC reaction

        Exclusion Criteria:

          -  have known contraindications or sensitivities to the use of any of the study
             medications(s) or their components.

          -  have any ocular condition or significant illness that, in the opinion of the
             investigator, could affect the subject's safety or trial parameters.

          -  had ocular surgical intervention within three (3) months prior to Visit 1 or during
             the study and/or a history of refractive surgery within the past 3 months;

          -  a known history of retinal detachment, diabetic retinopathy, or active retinal
             disease;

          -  the presence of an active ocular infection or positive history of an ocular herpetic
             infection at any visit.

          -  use of any disallowed medications during the period indicated prior to Visit 1 and
             during the study.

          -  have planned surgery during the trial period or within 30 days after.

          -  have an intraocular pressure that is less than 5 mmHg or greater than 22 mmHg or any
             type of glaucoma at Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rabia Ozden, OD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <disposition_first_submitted>February 28, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 3, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 7, 2012</disposition_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

